DENHAM SPRINGS – The Williamson Eye Center has performed the first procedure in Louisiana to implant the Hydrus Microstent, an innovative option for patients suffering from glaucoma.
Dr. Blake Booth performed the procedure on a patient on Thursday, April 11.
Cataract patients at the Williamson Eye Center will now have the option to treat their glaucoma with the Hydrus Microstent. The device is used to treat adult patients with mild to moderate primary open-angle glaucoma in conjunction with cataract surgery.
“A large percentage of cataract patients also have glaucoma and have traditionally been treated with topical medications indefinitely,” said Booth, cataract and refractive surgeon.
“The tasks of obtaining the medication and using it correctly were a burden on my patients,” he said.
“When I heard that it may be possible to help patients fight glaucoma with a microinvasive surgical option that reduced medication burden, I took it seriously.”
Glaucoma is a common eye disease that occurs due to pressure in the eye caused by buildup of excess fluid.
It is a leading cause of blindness worldwide, with more than 80 million people suffering from the disease.
A significant percentage of these patients also have cataracts.
With advances in minimally invasive glaucoma surgery (MIGS), patients may be able to address both concerns.
Roughly the size of an eyelash, the Hydrus Microstent is a next-generation MIGS device created to reduce eye pressure by re-establishing flow through Schlemm's canal, the eye's natural outflow pathway.
When placed into the trabecular meshwork and the canal during minimally invasive glaucoma surgery, the aqueous drainage device restores the flow of fluid in the eye using a Tri-ModalTM mechanism of action.
The device opens a bypass through a common source of flow blockage in the eye, known as the trabecular meshwork.
It then dilates and scaffolds, or keeps open, an important part of the eye called Schlemm’s canal to enhance flow.
The device spans a full 90 degrees within the eye.
This coverage ensures fluid reaches the eye’s drainage system, which carries fluid from Schlemm’s canal to the body’s circulatory system, and allows pressure in the eye to be lowered.
“Williamson Eye Center is excited to be introducing this new device into our practice and help improve our ability to treat patients with both glaucoma and cataracts,” Booth said.
“We consider the Hydrus Microstent an important advancement in lowering intraocular pressure in patients undergoing cataract surgery,” he said.
For more information on Hydrus® Microstent, contact the Williamson Eye Center at (225) 924-2020, or www.williamsoneye.com.
The Williamson Eye Center offers four locations, an outpatient surgery center, laser vision correction center, two cosmetic center locations, and three optical centers, as well as the support of 12 physicians, four physician assistants and more than 100 employees.
The microstent was developed by Ivantis Inc., of Irvine, Calif., a privately held company established in 2007 to design, develop and commercialize new technologies to treat eye disease.